Thalassemia Market to Witness Significant Growth by 2034 Driven by Emerging Gene and Cell Therapies Across the 7MM | DelveInsight

DelveInsight's "Thalassemia Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of thalassemia epidemiology, market, and clinical development in thalassemia, along with historical and forecasted epidemiology and market data, and a detailed analysis of the thalassemia therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore the intricate details of the Thalassemia Market Report @ https://www.delveinsight.com/report-store/thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Thalassemia Market Report
• In July 2026, Celgene announced result of A Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia.
• The Thalassemia Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• The World Health Organization reports suggest that about 60,000 infants are born with major thalassemia every year.
• Currently, there are no approved therapies for alpha thalassemia; however, certain therapies are approved for beta thalassemia, i.e., CASGEVY (Vertex Pharmaceuticals), ZYNTEGLO (Bluebird Bio), REBLOZYL (Bristol-Myers Squibb), and others.
• The pipeline for thalassemia is not very robust; however, key players like Agios Pharmaceuticals (PYRUKYND), Novo Nordisk (etavopivat), and Regeneron Pharmaceuticals (REGN7999) are conducting trials for the treatment of thalassemia patients.
• In January 2025, Agios Pharmaceuticals announced that the US FDA accepted for review the sNDA for mitapivat for the treatment of adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, with a Standard review classification and a PDUFA goal date of September 7, 2025.
• Awareness around thalassemia is steadily increasing, driven by advancements in diagnostics, improved management strategies, and the emergence of curative approaches such as stem cell and gene therapy.

Get a Free sample for the Thalassemia Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Thalassemia?
Thalassemia is a genetic blood disorder in which the body produces insufficient hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This results in fewer and less effective red blood cells, leading to anemia, marked by fatigue, weakness, and other symptoms due to reduced oxygen delivery to tissues. Thalassemia is inherited from one or both parents and varies in severity, from mild forms with little to no symptoms to severe forms requiring regular blood transfusions. It is more common in people of Mediterranean, Middle Eastern, South Asian, and African ancestry, and can affect either the alpha or beta part of hemoglobin, giving rise to alpha thalassemia or beta thalassemia, respectively.

Thalassemia Diagnosis
Thalassemia is typically diagnosed through a combination of medical history, family history, and specialized blood and genetic tests. If symptoms are mild or absent, it may be detected incidentally during a routine blood test; in more severe cases, signs often appear before the age of two. To confirm a diagnosis, healthcare providers may conduct a complete blood count (CBC), special hemoglobin tests to identify abnormal hemoglobin types, and genetic testing to determine the specific form of thalassemia.

Thalassemia Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Thalassemia
• Type-specific Diagnosed Prevalent Cases of Thalassemia
• Total Diagnosed Prevalent Cases of Thalassemia With Transfusion-dependency
• Total Treatable Cases of Thalassemia

Download the report to understand which factors are driving Thalassemia epidemiology trends @ https://www.delveinsight.com/report-store/thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Thalassemia Approved Therapies
• CASGEVY (exagamglogene autotemcel): Vertex Pharmaceuticals
CASGEVY is the first FDA-approved therapy utilizing CRISPR/Cas9 genome editing technology. It is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle-cell disease or transfusion-dependent beta thalassemia, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid-specific enhancer region of the BCL11A gene, resulting in the production of high levels of fetal hemoglobin (HbF) in red blood cells. In January 2024, Vertex Pharmaceuticals announced FDA approval of CASGEVY for transfusion-dependent beta thalassemia in patients 12 years and older.

• REBLOZYL (luspatercept): Bristol-Myers Squibb
REBLOZYL, a first-in-class therapeutic option, promotes late-stage red blood cell maturation. It is developed and commercialized through a global collaboration with Merck, and is indicated in the US for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. The US FDA approved REBLOZYL for this indication in November 2019.

Thalassemia Pipeline Analysis
• PYRUKYND (mitapivat): Agios Pharmaceuticals
PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the US, and for PK deficiency in adult patients in the European Union. The US FDA has accepted for review the sNDA for mitapivat for the treatment of adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. In June 2025, Agios presented new data on its PK activators, mitapivat and tebapivat, at the 30th European Hematology Association (EHA) Congress 2025.

• Etavopivat (FT-4202): Novo Nordisk
Etavopivat is a small-molecule activator of the enzyme Pyruvate Kinase R (PKR), which pushes red blood cells to produce energy while reducing 2,3-DPG levels, allowing stronger binding of oxygen to the faulty hemoglobin protein. This is intended to prevent red blood cells from taking on a sickle-like shape, prolonging red blood cell survival and easing anemia. It is currently being evaluated in Phase III for thalassemia in clinical trials, while per the company's pipeline the product is listed in Phase II for thalassemia.

Discover more about therapies set to grab major Thalassemia market share @ https://www.delveinsight.com/sample-request/thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Thalassemia Companies
Vertex Pharmaceuticals, Bluebird Bio, Bristol-Myers Squibb, Agios Pharmaceuticals, Novo Nordisk, Regeneron Pharmaceuticals, and others

Thalassemia Market Outlook
The thalassemia market is anchored by regular blood transfusions and iron chelation therapies to manage anemia and prevent iron overload. Curative options like stem cell transplants remain limited by donor availability. There are no marketed drugs for alpha thalassemia; however, marketed drugs for beta thalassemia include CASGEVY, ZYNTEGLO, and REBLOZYL. Emerging therapies such as PYRUKYND, aimed at reducing transfusion dependence, are expected to reshape the long-term treatment outlook. Key companies, including Agios Pharmaceuticals and Novo Nordisk, are evaluating their lead candidates in different stages of clinical development to investigate their products for the treatment of thalassemia.

Scope of the Thalassemia Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4 [Germany, France, Italy, and Spain], the UK, and Japan)
• Thalassemia Companies: Vertex Pharmaceuticals, Bluebird Bio, Bristol-Myers Squibb, Agios Pharmaceuticals, Novo Nordisk, Regeneron Pharmaceuticals, and others
• Thalassemia Therapies: CASGEVY, ZYNTEGLO, REBLOZYL, PYRUKYND, Etavopivat, REGN7999, and others
• Thalassemia Therapeutic Assessment: Thalassemia current marketed and emerging therapies
• Thalassemia Market Dynamics: Thalassemia market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Thalassemia Unmet Needs, KOL's views, Analyst's views, Thalassemia Market Access and Reimbursement

To know more about Thalassemia companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Thalassemia
4. Key Events of Thalassemia
5. Epidemiology and Market Methodology of Thalassemia
6. Thalassemia: Market Overview at a Glance
7. Disease Background and Overview: Thalassemia
8. Treatment and Guidelines
9. Epidemiology and Patient Population
10. Patient Journey of Thalassemia
11. Marketed Drugs for Thalassemia
12. Emerging Therapies of Thalassemia
13. Thalassemia: Seven Major Market Size
14. Unmet Needs of Thalassemia
15. SWOT Analysis of Thalassemia
16. KOL Views of Thalassemia
17. Market Access and Reimbursement of Thalassemia
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.